Home > Cardiology > Apixaban plus P2Y12 inhibitor likely best for AF after ACS or PCI

Apixaban plus P2Y12 inhibitor likely best for AF after ACS or PCI


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
Journal of the American College of Cardiology
Reuters Health - 31/01/2022 - In patients with atrial fibrillation (AF) after acute coronary syndromes (ACS) and/or percutaneous intervention (PCI), antithrombotic therapy with apixaban plus a P2Y12 inhibitor without aspirin is likely best, regardless of bleeding risk, researchers say. In the AUGUSTUS trial, "we showed that a regimen that includes apixaban plus a P2Y12 inhibitor like clopidogrel without aspirin is effective and the safest strategy for these patients," Dr. Renato Lopes of Duke University School of Medicine in Durham told Reuters Health by email. "In the current analysis," he said, "we extended these results, demonstrating that this regimen provides the greatest benefit to patients, irrespective of their stroke and bleeding risks (and) can be effectively and safely used across the spectrum of risks, according to the CHADSVASC and HASBLED scores." As reported in the Journal of the American College of Cardiology, Dr. Lopes and colleagues conducte...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on